Regenics Board of Directors 2020

Members Elected at the General Assembly June 24th 2020 and Extraordinary General Assembly October 16th 2020.

Runhild Gammelsæther, Board MemberRunhild was elected to the Board October 2020. Runhild Gammelsæter aged 44, has a PhD in cell physiology from the Faculty of medicine at the University of Oslo. She comes from positions as Medical Director in GlaxoSmithKline (GSK) Norway og Associate Scientific Director i AbbVie Inc. Runhild Gammelsæther now serves as an  «independent entreprenour» where she covers roles as Chief Medical Officer in InsuLife  AS and Global Medical Director i Arctic Nutrition AS. 


Tore Heldrup Rasmussen, MBA, Founder, Chairman of the Board. Mr. Rasmussen has been heading up several successful biotechnology companies prior to co-founding Regenics. Mr. Rasmussen brings many years of experience in strategy development and consumer products, as a Partner in MarkUp Consulting in Oslo and through tenures with Procter & Gamble and Orkla Foods (Norway). Mr. Rasmussen has an MBA degree from the University of Michigan.


Jan Alan Alfheim, Board Member, Jan A. Alfheim joined to the Board of Regenics AS in June 2020.  Mr. Alfheim is currently the CEO of Oncoinvent AS, a leading oncology company In Norway. Jan is a business executive with thirty-five years’ experience in the chemical and pharmaceutical markets and has experience in research, project management, business development & partnering, company start-ups, and product launches.   Prior to joining Oncoinvent, Alfheim held various senior roles including CEO and COO of Nordic Nanovector ASA, CBO at Clavis Pharma, President and Board Member of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc in Chemistry from Concordia University and a MBA from McGill University.


Wilhelm Holst, Board member. Wilhelm Holst joined the Board of Regenics AS in 2018 alongside an investment in the company. He has extensive experience from the shipping industry, coming from CEO and COO roles at Lorentzen & Stemoco and RS Platou. Wilhem has through a long service in the Norwegian shipping industry added nextensive experience in Shipbroking and head of S&P roles. He now runs his own investment activity through Whl Invest and has additional Board positions in Aksel L Hansson AS, Flamier AS, High Seas AS and VotWear AS.


Harald Nordal, MSc, MBA. Board member. Harald is now re-elected to the board having served at the board of Regenics AS for extensive periods. Harald is cofounder and leads the board of Arctic Nutrition AS and Hyperthermics AS. Harald is also CEO of Life Capitol AS, one of Regenics founders and largest shareholders. He has extensive national and international board experience within biotech and life science. Harald has held senior management position in Statoil(Equinor ASA), Ulstein International AS, Kværner Kleven AS and Innovation Norway. 



Philippe Collas, PhD, Founder, Director and Scientific Adviser. Dr. Collas has previously served on the Regenics Board of Directors. He is Professor at the Institute of Medical Biochemistry of the University of Oslo, Norway, where he directs a laboratory of 20 people. Dr. Collas holds an engineering degree from France and a PhD from the University of Massachusetts. He has tremendous experience in research on nuclear reprogramming from academia (University of Massachusetts, Amherst College, University of Oslo) and industry in the United States. He was a co-founder of Nucleotech LLC (USA) and has served as Consultant for several Biotech Companies in Europe, United States and Australia. He has developed cell-free systems to investigate nuclear dynamics and gene function and has published over 100 scientific articles in the area of nuclear reprogramming. He was the first to show that somatic cells can be reprogrammed using cellular extracts. Dr. Collas is member of the Norwegian Academy of Science and Letters.



Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.